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genetic analysisLetter to the Editor concerns the question of a discussion of awake porcine malignant hyperthermia that
erroneously omits the awake human stress reaction of malignant hyperthermia.9.
).
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D.H.Maclennan, E. Zvaritch, Mechanistic models formuscle diseases
and disorders originating in the sarcoplasmic reticulum, Biochim.
Biophys. Acta 1813 (2011) 948-964.
Drs. MacLennan and Zvaritch have a commendable presentation on
muscle disorders related to sarcoplasmic reticulum. However, we
call attention to their statement, page 950, left column, lines 6–9,
that, while swine can trigger into a malignant hyperthermia (MH)
reaction under stressful conditions, humans donot. Speciﬁcally, they
state,
“… triggering of an MH reaction, … requires the presence of both
a causal mutation and either a triggering anesthetic, or, in the case
of pigs, stressful conditions.”
Yet there is indisputable evidence that humans susceptible to MH
have stress-related abnormal responses in the absence of exposure to
triggering anesthetic agents:
Patient1: In the late 1970s, this 42 y/o5′10″ (175 cm)200 lb (90 kg)
white male came to the Mayo Clinic in Rochester for evaluation of
periodic stressful overheating [1]. Evaluation by the internist Dr.
Thompson reminded him of a presentation on MH provided byDr. Gronert at an Internal Medicine seminar, and he requested my
evaluation.
For the past 20–25 years extreme physical or emotional stress or
fatigue had resulted in aching joints, malaise, fevers of 40 °C (104 °F)
or more, and soaking sweats. These persisted despite use of aspirin
and surface cooling. This ‘fever’ would break after 3–4 days. Prior
medical workups documented these. Laboratory abnormalities oc-
curred only during episodes and included mild hyperglycemia and aose–response curves of the patient's muscle compared to mean
s from a normal population. Note the shift to the left, indicating a
affeine in the presence or absence of halothane, lo. Optimal length.
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resulted in these episodes.
An extensive Mayo workup was normal except for skeletal muscle
contracture responses to determine susceptibility to MH. At this time,
national standardized contracture testing did not exist, and we
compared his responses to normal values we had determined in
normal humans [2].
His values differed from normal (Fig. 1 from [1]), consistent with
susceptibility to MH:
We advised use of oral dantrolene when these symptoms recurred
at home. It was wonderfully effective and “turned his life around.” He
could now be active physically without worry. The effective dose was
1.1 mg/kg; it relieved the symptoms within 2–3 h, also producing a
mild weakness.
We have communicated over the years; in fall 2010 he related that
he continues dantrolene control as needed, same dose. Several years
after we diagnosed him as MH susceptible, he had added surgery at
Mayo; he did ﬁne with non-triggering agents, but, upon emergence
and awakening, his symptoms began to recur, and were effectively
treated with intravenous dantrolene.
Thepatientwas enrolled in a studyofMHgenetics through theNorth
American MH registry. Screening of 64 exons in the RYR1 gene did not
identify a variant but screening of gene coding for myoadenylate
deaminase (AMPD1 gene) revealed two mutations Q12X and P48L
which are associated with AMPD1 deﬁciency, the most common
enzyme defect in humans [3].
Patient 2: A 12 y/o boy developed MH during sevoﬂurane anesthesia
for treatment of a humerus fracture [4]. Fifteen minutes after induc-
tion, end expired CO2 abruptly increased to more than 70 mmHg,
pulse rate to 150, temperature from 36.7° to 39.4 °C. Diaphoresis
became evident. Treatment included dantrolene. CK, later, was 9049
International Units (IU). He recovered uneventfully.
Eight months later, he played football when the outside temper-
ature was 80 °F (26 °C). After the game, he felt hot, was diaphoretic,
and hyperventilated. He described tingling in his limbs. He convulsed,
and had a respiratory arrest. His ECG showed a sinus tachycardia of
136. Jaw trismus prevented tracheal intubation. He developed
ventricular ﬁbrillation. Treatment included epinephrine and deﬁbril-
lation. At the hospital, his rectal temperature was N108 °F (42.2 °C).
He had a wide complex bradycardia, and, again, ventricular
ﬁbrillation. His trachea was intubated without relaxant. Treatment
included bicarbonate, calcium, glucose, insulin, and dantrolene.
Arterial sample: pH 6.76, PCO2 115, PO2 22, K+8.8 mEq/l, increasing
to 14.5 mEq/L. Resuscitationwas halted after an hour. He had full rigorpost mortem, and muscle histology was not grossly abnormal. Both
the boy and his father had a mutation, R163C, in the RYR1 gene.
Patient 3: A 7 month old male was given nitrous oxide/oxygen/
halothane (0.5–1%) as anesthesia for bilateral ptosis repair [5]. He
became dusky and rigid. Halothane was discontinued, 100%
oxygen was started, and surgery was canceled. Rectal temperature
peaked at 100 °F. CK 8 h later was 1883 IU.
At 20 months of age he had his ﬁrst non-anesthetic MH-like event;
this seemed to be related to a high environmental temperature. Over
the next four years he had multiple episodes of muscle stiffness with
fever, tachycardia, CK values to 100,000 IU, and hyperkalemia,
associated with upper respiratory infections, or, even, spontaneously.
Treatment consisted of cooling, analgesics, and dantrolene. At age 5,
muscle biopsy data showed a contracture of 10 g to 3% halothane and
1.2 g with 2 mM caffeine, diagnostic of susceptibility to MH. During
one of his febrile episodes, he died while en route to a hospital.
Patient 4: A 6 y/o girl was hospitalized with fever 102.7 °F (39.3 °C),
rigidity, trismus, and emesis [5]. (In the past, she'd had a spontan-
eous episode of fever N105 °F (40.6 °C) plus total body and jaw
muscle rigidity.) Despite therapy, she deteriorated, with tempera-
ture 108 °F (42.2°). Asystole occurred, cardiopulmonary resuscita-
tion began, and intravenous dantrolene 10 mg/kg was given. She
died despite 2 h cardiopulmonary resuscitation. Autopsy was
unremarkable.
In both patients 3 and 4, genetic testing showed a novel amino acid
change, Arg to Cys, at position 3983 (exon 87) of the RYR1 gene [5]. Arg at
position 3983 is highly conserved among ryanodine subtypes and across
species. This change was absent in all of 280 control chromosomes.
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